Navigation Links
NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Date:3/18/2008

SAN MATEO, Calif., March 18 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will report results for its fourth quarter and year-end 2007 on Wednesday, March 26, 2008, after the market closes.

A conference call to review the results will begin at 5:00 p.m. ET (2:00 p.m. PT) on March 26, 2008 and will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer.

To participate in the conference call, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). In addition, a dial-up replay of the conference call will be available beginning March 26, 2008 at 8:00 p.m. ET (5:00 p.m. PT) and ending on April 5, 2008. The replay telephone number is 1- 877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 275941.

A live web cast of the call will also be available from the Investor Relations section on the corporate web site at http://www.neurogesx.com. A web cast replay can be accessed on the corporate web site beginning March 26, 2008 at approximately 6:00 p.m. ET. The replay will remain available until April 26, 2008.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements concerning future presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc. The Ruth Group

Stephen Ghiglieri Investors / Media

(650) 358-3300 Stephanie Carrington / Jason Rando

(646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
2. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
3. NeurogesX Closes $25 Million Private Placement
4. NeurogesX, Inc. Announces $25 Million Private Placement
5. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
6. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. NeurogesX Expands Senior Management Team
8. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
9. NeurogesX Appoints New Director to the Board
10. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
11. Vion Reports 2007 Fourth Quarter and Year-End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Palo Alto, CA, USA (PRWEB) , ... March 29, 2017 , ... ... experts in various regulatory subjects has announced its 3rd Annual Medical Device Summit 2017 ... 2017 at the Omni Parker House Hotel, in Boston, MA. , The Omni Parker ...
(Date:3/29/2017)... 29, 2017  Halozyme Therapeutics, Inc. (NASDAQ: HALO), ... therapies, today announced that an Oncologic Drug Advisory ... voted 11 to 0 that the benefit/risk of ... favorable for patients in the proposed indications of ... lymphocytic leukemia. The FDA action date is June ...
(Date:3/29/2017)... ... March 29, 2017 , ... ACEA Biosciences, ... disperses a quarterly travel award to noteworthy scientists who will be presenting research ... its new round of awards are being given to two postdoctoral fellows studying ...
(Date:3/29/2017)... ... 29, 2017 , ... Bactana Animal Health, a company developing natural products aimed ... enhancement of the gut microbiota, today announced the closing of its first round of ... Sustainable Income Capital Management, LLC and a number of private investors. The company will ...
Breaking Biology Technology:
(Date:2/14/2017)...  Wake Forest Baptist Medical Center today announced Julie Ann ... officer (CEO). Freischlag joins the medical center on May ... M.D., who last year announced that he would transition ... leading it since 2008.   As CEO, ... Baptist,s academic health system, which includes Wake Forest School ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
Breaking Biology News(10 mins):